SecBot SecBot
PRESS-RELEASE ·Filed Aug 5, 2026

ARQT

Arcutis Biotherapeutics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The raised FY guidance and sustained profitability signal accelerating commercial execution. Monitor Q4 2026 for vitiligo Phase 2 data and the February 2027 PDUFA for the infant atopic dermatitis sNDA, both potential catalysts. The stock's strong momentum may continue, but the 86% bullish analyst consensus already reflects high expectations.

DirectionBullish
Confidencehigh
Horizonweeks

ZORYVE

▲ Bullish Named in this press release
Impact
Phase
Approved (commercial stage)
Time to market
Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
Next catalyst
PDUFA date · Feb 23, 2027 99d

What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$26.43
T+0 close · Aug 5, 2026 · via day close
Latest settled
+21.34%
T+60 · $32.07
Vs SPY
+23.01%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 6 $26.43entry
  2. T+1 · 3mo ago −4.31%α −4.92% · $25.29
  3. T+5 · 3mo ago −2.27%α −3.48% · $25.83
  4. T+20 · 3mo ago −10.48%α −11.08% · $23.66
  5. T+60 · 18d ago +21.34%α +23.01% · $32.07
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcutis reported Q2 2026 product revenue of $129.9M (+59% YoY) and net income of $15.0M ($0.11 EPS), a significant turnaround from a net loss of -$15.9M in Q2 2025. The company raised full-year 2026 net product sales guidance from $480-495M to $525-540M, reflecting strong ZORYVE demand and improved gross-to-net pricing. Despite the EPS miss vs consensus ($0.11 actual vs $0.05 estimate, a +120% beat), the stock is likely to react positively to the revenue beat, raised guidance, and sustained positive operating cash flow of $12.6M.

Key Financial Metrics

EPS
$0.11
est $0.05 · +120.0%
Revenue
$129.9M
est $118.9M · +9.2% · +59.0% YoY
Rating
strong beat
Guidance
$525M-$540M
raised
Gross Margin
91.58%

Key Facts

  • Q2 2026 product revenue of $129.9M (+59% YoY, +23% sequential)
  • Net income of $15.0M ($0.11 EPS) vs net loss of -$15.9M in Q2 2025
  • Raised FY2026 net product sales guidance to $525-540M from $480-495M
  • Positive operating cash flow of $12.6M in Q2 2026
  • FDA approved ZORYVE cream 0.3% for children with plaque psoriasis down to age 2
  • FDA accepted sNDA for ZORYVE cream 0.05% in infants with atopic dermatitis (PDUFA Feb 23, 2027)
  • Completed enrollment of Phase 2 vitiligo study; topline results expected Q4 2026

Financial Impact

Q2 revenue $129.9M (+59% YoY); raised FY guidance by $45M at midpoint to $532.5M; net income $15.0M vs loss of -$15.9M YoY

revenuenet incomeguidancecash flow

Risk Factors

  • Competition from other topical therapies in psoriasis and atopic dermatitis
  • Execution risk on sales force expansion into primary care and pediatrics
  • Pipeline setbacks (vitiligo Phase 2 data, ARQ-234 Phase 1a/1b)
  • Dependence on ZORYVE franchise for all revenue

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3339629

US Market Status

Market Closed · Opens Wed (10h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 5, 2026